WEDNESDAY, Sept. 6, 2017 -- The inhaler medication Spiriva (tiotropium bromide) may help slow the progression of COPD if given in the early stages of the disease, a new study suggests. Researchers ...

Long-term, Head-to-Head Study Showed SPIRIVA HandiHaler (tiotropium bromide inhalation powder) Significantly Prolonged Time to First Moderate or Severe COPD Exacerbation versus Salmeterol HFA-MDI The ...

-- Patients to Benefit From Easy-to-Use Inhaler With Enhanced Drug Delivery Boehringer Ingelheim and Pfizer today announced successful completion of the approval process for authorisation to market ...

FDA recently accepted sNDA filing to review data from DYNAGITO trial for inclusion in Stiolto Respimat label A COPD exacerbation, or a flare-up, is a sudden worsening of symptoms, such as increased ...

RIDGEFIELD, Conn., Feb. 16, 2017 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT for the long-term ...

Major League Baseball’s annual All-Star Game last night featured new DTC spots for Spiriva HandiHaler, an inhaler indicated for chronic bronchitis and emphysema. The television spots were created by ...

Tiotropium as Asthma Add-On Treatment Shows Promise Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) Inhalation Spray is now available. The Respimat formulation uses ...

RIDGEFIELD, Conn., September 16, 2015 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved SPIRIVA RESPIMAT for the long-term, ...

RIDGEFIELD, Conn., August 19, 2014 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose ...

RIDGEFIELD, Conn. & NEW YORK--(BUSINESS WIRE)--A new study, published today in The New England Journal of Medicine (NEJM), showed that SPIRIVA ® HandiHaler ® (tiotropium bromide inhalation powder), a ...